Abeona Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Abeona Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Abeona Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Abeona Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Abeona Therapeutics Inc (Abeona) is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies. The company develops therapies for conditions such as recessive dystrophic epidermolysis bullosa (RDEB) and various ophthalmic diseases. Abeona's major products include prademagene zamikeracel (pz-cel) and adeno-associated virus (AAV) based gene therapies. The company is also developing ABO-503 for X-linked Retinoschisis (XLRS), ABO-504 for Stargardt Disease, and ABO-505 for Autosomal Dominant Optic Atrophy (ADOA), using various gene therapy approaches. It has licensing agreements with Ultragenyx Pharmaceutical Inc for Sanfilippo syndrome type A and with Taysha Gene Therapies Inc for CLN1 disease and Rett syndrome. The company utilizes its AIM capsids platform, which is licensed from the University of North Carolina at Chapel Hill, to enhance its gene therapy offerings. The company operates a cGMP manufacturing facility in Cleveland, Ohio. Abeona is headquartered in Cleveland, Ohio, the US.
Headquarters
United States of America
Address
4th Floor, 6555 Carnegie Avenue, Cleveland, Ohio, 44103
Website
www.abeonatherapeutics.com
Telephone
1 646 8134701
No of Employees
226
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABEO (NASD)
Revenue (2025)
$5.8M
-100%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
211.7%
(2025 vs 2024)
Market Cap*
$323.1M
Net Profit Margin (2025)
XYZ
143.6%
(2025 vs 2024)
* As of and is in US$
Abeona Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | VIITAL |
| pz-cel: Recessive Dystrophic Epidermolysis Bullosa (RDEB) | AIM |
| ABO-504: Stargardt Disease | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2020 | Contracts/Agreements | In August, the company entered into an inventory purchase agreement with Taysha Gene Therapies for ABO-202 to treat CLN1 disease. |
| 2019 | Regulatory Approval | In June, the company received Fast Track designation to its ABO-202 program by the US FDA for the treatment of patients with CLN1 disease. |
| 2019 | Regulatory Approval | In April, Abeona received FDA fast track designation for ABO-101 for treatment of Sanfilippo Syndrome Type B (MPS IIIB). |
Competitor Comparison
| Key Parameters | Abeona Therapeutics Inc | Grifols SA | Jazz Pharmaceuticals Plc | Krystal Biotech Inc | Camurus AB |
|---|---|---|---|---|---|
| Headquarters | United States of America | Spain | Ireland | United States of America | Sweden |
| City | Cleveland | Sant Cugat Del Valles | Dublin | Pittsburgh | Lund |
| State/Province | Ohio | Barcelona | Dublin | Pennsylvania | - |
| No. of Employees | 226 | 23,822 | 2,890 | 295 | 285 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Amoroso | Chairman | Executive Board | 2021 | 47 |
| Vishwas Seshadri, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2021 | 49 |
| Joseph Vazzano | Chief Financial Officer | Senior Management | - | 41 |
| Brendan O’Malley, Ph.D. | Chief Legal Officer; General Counsel | Senior Management | 2021 | 56 |
| Brian Kevany, Ph.D. | ; Chief Scientific Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer